Matthias Guckenberger
@mguckenberger.bsky.social
Passionate Radiation Oncologist
Chairman University Hospital Zurich
Professor University of Zurich
President of ESTRO
Chairman University Hospital Zurich
Professor University of Zurich
President of ESTRO
Fresh from #ASCO2025
meetings.asco.org/abstracts-pr...
SBRT vs microwave ablation (MWA) in pts with CRC liver oligo-mets
➡️ n=100, n=92 treated (39 SBRT, 53 MWA)
➡️ 18/92 pts (20%) reported side effects
➡️ n=3 G3-4 pain; n=2 infections after open MWA, n=1 bowelperforation after percutaneous MWA
meetings.asco.org/abstracts-pr...
SBRT vs microwave ablation (MWA) in pts with CRC liver oligo-mets
➡️ n=100, n=92 treated (39 SBRT, 53 MWA)
➡️ 18/92 pts (20%) reported side effects
➡️ n=3 G3-4 pain; n=2 infections after open MWA, n=1 bowelperforation after percutaneous MWA
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 25, 2025 at 8:28 AM
Fresh from #ASCO2025
meetings.asco.org/abstracts-pr...
SBRT vs microwave ablation (MWA) in pts with CRC liver oligo-mets
➡️ n=100, n=92 treated (39 SBRT, 53 MWA)
➡️ 18/92 pts (20%) reported side effects
➡️ n=3 G3-4 pain; n=2 infections after open MWA, n=1 bowelperforation after percutaneous MWA
meetings.asco.org/abstracts-pr...
SBRT vs microwave ablation (MWA) in pts with CRC liver oligo-mets
➡️ n=100, n=92 treated (39 SBRT, 53 MWA)
➡️ 18/92 pts (20%) reported side effects
➡️ n=3 G3-4 pain; n=2 infections after open MWA, n=1 bowelperforation after percutaneous MWA
Neoadjuvant chemo-IO for Borderline Resectable & Unresectable Stage III NSCLC
Conclusion of authors: "high rates of surgical resectability"
Pts with completed surgery:
III A: 65/79 - 82%
III B: 16/27 - 59%
III C: 3/6 - 50%
-> careful interpretation needed
jamanetwork.com/journals/jam...
Conclusion of authors: "high rates of surgical resectability"
Pts with completed surgery:
III A: 65/79 - 82%
III B: 16/27 - 59%
III C: 3/6 - 50%
-> careful interpretation needed
jamanetwork.com/journals/jam...
PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
This cohort study evaluates the efficacy of neoadjuvant programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) blockade combined with chemotherapy in enhancing surgical out...
jamanetwork.com
May 25, 2025 at 7:59 AM
Neoadjuvant chemo-IO for Borderline Resectable & Unresectable Stage III NSCLC
Conclusion of authors: "high rates of surgical resectability"
Pts with completed surgery:
III A: 65/79 - 82%
III B: 16/27 - 59%
III C: 3/6 - 50%
-> careful interpretation needed
jamanetwork.com/journals/jam...
Conclusion of authors: "high rates of surgical resectability"
Pts with completed surgery:
III A: 65/79 - 82%
III B: 16/27 - 59%
III C: 3/6 - 50%
-> careful interpretation needed
jamanetwork.com/journals/jam...
🔥 SAVE THE DATE 🔥
❓ What is the population-health effect of novel anti-cancer drugs
❓ How do anti-cancer drugs compare to other drugs and health services
❓ How to improve sustainability of cancer care and medicine in the future
Virtual Grand Rounds in Radiation Oncology
www.usz.ch/veranstaltun...
❓ What is the population-health effect of novel anti-cancer drugs
❓ How do anti-cancer drugs compare to other drugs and health services
❓ How to improve sustainability of cancer care and medicine in the future
Virtual Grand Rounds in Radiation Oncology
www.usz.ch/veranstaltun...
January 27, 2025 at 8:49 PM
🔥 SAVE THE DATE 🔥
❓ What is the population-health effect of novel anti-cancer drugs
❓ How do anti-cancer drugs compare to other drugs and health services
❓ How to improve sustainability of cancer care and medicine in the future
Virtual Grand Rounds in Radiation Oncology
www.usz.ch/veranstaltun...
❓ What is the population-health effect of novel anti-cancer drugs
❓ How do anti-cancer drugs compare to other drugs and health services
❓ How to improve sustainability of cancer care and medicine in the future
Virtual Grand Rounds in Radiation Oncology
www.usz.ch/veranstaltun...
Thought provoking !
Population-health impact of new drugs recommended by NICE in England during 2000–20
- quality-adjusted life-years and incremental cost-effectiveness ratio used for analysis
👉 overall NEGATIVE (!) cumulative impact
👉 data for #radonc ?
www.thelancet.com/journals/lan...
Population-health impact of new drugs recommended by NICE in England during 2000–20
- quality-adjusted life-years and incremental cost-effectiveness ratio used for analysis
👉 overall NEGATIVE (!) cumulative impact
👉 data for #radonc ?
www.thelancet.com/journals/lan...
January 5, 2025 at 10:29 AM
Thought provoking !
Population-health impact of new drugs recommended by NICE in England during 2000–20
- quality-adjusted life-years and incremental cost-effectiveness ratio used for analysis
👉 overall NEGATIVE (!) cumulative impact
👉 data for #radonc ?
www.thelancet.com/journals/lan...
Population-health impact of new drugs recommended by NICE in England during 2000–20
- quality-adjusted life-years and incremental cost-effectiveness ratio used for analysis
👉 overall NEGATIVE (!) cumulative impact
👉 data for #radonc ?
www.thelancet.com/journals/lan...
Retrospective multicenter study of SBRT for pulmonary oligometastatic HNSCC
- 16 centers, 178 pts, 284 pulmonary mets
- 1a local failure rate 5.5%
- no grade 4/5 toxicities
👉 supporting prospective evaluation, in preparation by
EORTC & P Balermpas
www.redjournal.org/article/S036...
- 16 centers, 178 pts, 284 pulmonary mets
- 1a local failure rate 5.5%
- no grade 4/5 toxicities
👉 supporting prospective evaluation, in preparation by
EORTC & P Balermpas
www.redjournal.org/article/S036...
DEFINE_ME
www.redjournal.org
January 5, 2025 at 10:12 AM
Retrospective multicenter study of SBRT for pulmonary oligometastatic HNSCC
- 16 centers, 178 pts, 284 pulmonary mets
- 1a local failure rate 5.5%
- no grade 4/5 toxicities
👉 supporting prospective evaluation, in preparation by
EORTC & P Balermpas
www.redjournal.org/article/S036...
- 16 centers, 178 pts, 284 pulmonary mets
- 1a local failure rate 5.5%
- no grade 4/5 toxicities
👉 supporting prospective evaluation, in preparation by
EORTC & P Balermpas
www.redjournal.org/article/S036...
Aiming to refine your #radonc in 2025 !
Offer RT for low-volume metastatic PC, only ?
What benefit of RT is to be communicated to pts & colleagues ?
How about SBRT or surgery ?
Virtual Grand Rounds in Radiation Oncology
Jan 8th / 17:00 - 17:30 CET
Dr Alberto Bossi
👇
www.usz.ch/veranstaltun...
Offer RT for low-volume metastatic PC, only ?
What benefit of RT is to be communicated to pts & colleagues ?
How about SBRT or surgery ?
Virtual Grand Rounds in Radiation Oncology
Jan 8th / 17:00 - 17:30 CET
Dr Alberto Bossi
👇
www.usz.ch/veranstaltun...
January 2, 2025 at 9:27 AM
Aiming to refine your #radonc in 2025 !
Offer RT for low-volume metastatic PC, only ?
What benefit of RT is to be communicated to pts & colleagues ?
How about SBRT or surgery ?
Virtual Grand Rounds in Radiation Oncology
Jan 8th / 17:00 - 17:30 CET
Dr Alberto Bossi
👇
www.usz.ch/veranstaltun...
Offer RT for low-volume metastatic PC, only ?
What benefit of RT is to be communicated to pts & colleagues ?
How about SBRT or surgery ?
Virtual Grand Rounds in Radiation Oncology
Jan 8th / 17:00 - 17:30 CET
Dr Alberto Bossi
👇
www.usz.ch/veranstaltun...
Virtual Grand Rounds in Radiation Oncology
Let`s start 2025 with another highly-important lecture
Jan 8th 2025 - 17:00 - 17:30
Dr. Alberto Bossi
Radiotherapy of the primary in metastatic prostate cancer - insights from PEACE-1
Link 👇
www.usz.ch/veranstaltun...
Let`s start 2025 with another highly-important lecture
Jan 8th 2025 - 17:00 - 17:30
Dr. Alberto Bossi
Radiotherapy of the primary in metastatic prostate cancer - insights from PEACE-1
Link 👇
www.usz.ch/veranstaltun...
December 24, 2024 at 8:42 AM
Virtual Grand Rounds in Radiation Oncology
Let`s start 2025 with another highly-important lecture
Jan 8th 2025 - 17:00 - 17:30
Dr. Alberto Bossi
Radiotherapy of the primary in metastatic prostate cancer - insights from PEACE-1
Link 👇
www.usz.ch/veranstaltun...
Let`s start 2025 with another highly-important lecture
Jan 8th 2025 - 17:00 - 17:30
Dr. Alberto Bossi
Radiotherapy of the primary in metastatic prostate cancer - insights from PEACE-1
Link 👇
www.usz.ch/veranstaltun...
Season's Greetings
December 23, 2024 at 1:48 PM
Season's Greetings
Safe practice of spine SBRT requires high-quality data about SC dose tolerance
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...
Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy
This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.
jamanetwork.com
December 19, 2024 at 9:09 PM
Safe practice of spine SBRT requires high-quality data about SC dose tolerance
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...
Todas is HCC day!
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
jamanetwork.com
December 19, 2024 at 8:57 PM
Todas is HCC day!
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
And yet another prospective trial confirming excellent efficacy of SBRT for localized HCC
- n=36 pts
- median tumor size 2.3 cm
- median FU 49 mo
- 3-year local control rate 93%
- Grade 3 AE 11%
www.redjournal.org/article/S036...
- n=36 pts
- median tumor size 2.3 cm
- median FU 49 mo
- 3-year local control rate 93%
- Grade 3 AE 11%
www.redjournal.org/article/S036...
December 19, 2024 at 8:35 AM
And yet another prospective trial confirming excellent efficacy of SBRT for localized HCC
- n=36 pts
- median tumor size 2.3 cm
- median FU 49 mo
- 3-year local control rate 93%
- Grade 3 AE 11%
www.redjournal.org/article/S036...
- n=36 pts
- median tumor size 2.3 cm
- median FU 49 mo
- 3-year local control rate 93%
- Grade 3 AE 11%
www.redjournal.org/article/S036...
Randomized comparison of SBRT vs RFA for recurrent small HCC (n=166 pts)
👆 Freedom from local progression significantly improved after SBRT: 2a 92.7% vs 75.8%, HR=0.45 !
👉 No difference in PFS (median 37.6 vs 27.6mo) and OS (2a 97.6% vs 93.9%)
👍
ascopubs.org/doi/10.1200/...
👆 Freedom from local progression significantly improved after SBRT: 2a 92.7% vs 75.8%, HR=0.45 !
👉 No difference in PFS (median 37.6 vs 27.6mo) and OS (2a 97.6% vs 93.9%)
👍
ascopubs.org/doi/10.1200/...
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial
PURPOSETo assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic
body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC).METHODSIn this trial, ...
ascopubs.org
December 19, 2024 at 7:32 AM
Randomized comparison of SBRT vs RFA for recurrent small HCC (n=166 pts)
👆 Freedom from local progression significantly improved after SBRT: 2a 92.7% vs 75.8%, HR=0.45 !
👉 No difference in PFS (median 37.6 vs 27.6mo) and OS (2a 97.6% vs 93.9%)
👍
ascopubs.org/doi/10.1200/...
👆 Freedom from local progression significantly improved after SBRT: 2a 92.7% vs 75.8%, HR=0.45 !
👉 No difference in PFS (median 37.6 vs 27.6mo) and OS (2a 97.6% vs 93.9%)
👍
ascopubs.org/doi/10.1200/...
Remember the misleading press about "brutal" #radonc after PROSPECT ?
This is what modern RT can achieve for elderly breast cancer patients !
👉 "Endocrine Tx was associated with a greater reduction in HRQOL compared with RT at 24 mo"
👉 oncological data awaited
www.thelancet.com/journals/lan...
This is what modern RT can achieve for elderly breast cancer patients !
👉 "Endocrine Tx was associated with a greater reduction in HRQOL compared with RT at 24 mo"
👉 oncological data awaited
www.thelancet.com/journals/lan...
December 15, 2024 at 9:23 PM
Remember the misleading press about "brutal" #radonc after PROSPECT ?
This is what modern RT can achieve for elderly breast cancer patients !
👉 "Endocrine Tx was associated with a greater reduction in HRQOL compared with RT at 24 mo"
👉 oncological data awaited
www.thelancet.com/journals/lan...
This is what modern RT can achieve for elderly breast cancer patients !
👉 "Endocrine Tx was associated with a greater reduction in HRQOL compared with RT at 24 mo"
👉 oncological data awaited
www.thelancet.com/journals/lan...
ESTRO power team !
Anna Kirby and Barbara Jereczek-Fossa as past-president and president-elect
Thanks you so much for your 💪 collaboration, friendship and dedication, to
👉 advance multidisciplinary cancer care
👉 elevate radiation oncology
👉 develop ESTRO society
Anna Kirby and Barbara Jereczek-Fossa as past-president and president-elect
Thanks you so much for your 💪 collaboration, friendship and dedication, to
👉 advance multidisciplinary cancer care
👉 elevate radiation oncology
👉 develop ESTRO society
December 15, 2024 at 9:10 PM
ESTRO power team !
Anna Kirby and Barbara Jereczek-Fossa as past-president and president-elect
Thanks you so much for your 💪 collaboration, friendship and dedication, to
👉 advance multidisciplinary cancer care
👉 elevate radiation oncology
👉 develop ESTRO society
Anna Kirby and Barbara Jereczek-Fossa as past-president and president-elect
Thanks you so much for your 💪 collaboration, friendship and dedication, to
👉 advance multidisciplinary cancer care
👉 elevate radiation oncology
👉 develop ESTRO society
Radiation Oncology is characterized by rapid innovation
Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice
Well written review by Erin Gillespie and colleagues 👇
www.redjournal.org/article/S036...
Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice
Well written review by Erin Gillespie and colleagues 👇
www.redjournal.org/article/S036...
DEFINE_ME
www.redjournal.org
December 7, 2024 at 9:32 AM
Radiation Oncology is characterized by rapid innovation
Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice
Well written review by Erin Gillespie and colleagues 👇
www.redjournal.org/article/S036...
Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice
Well written review by Erin Gillespie and colleagues 👇
www.redjournal.org/article/S036...
In case you may have missed any of the
Virtual Grand Rounds in Radiation Oncology lectures
Recordings are 👇
youtube.com/playlist?lis...
Endorsed by:
ESTRO
DEGRO
SASRO
Virtual Grand Rounds in Radiation Oncology lectures
Recordings are 👇
youtube.com/playlist?lis...
Endorsed by:
ESTRO
DEGRO
SASRO
December 5, 2024 at 2:12 PM
In case you may have missed any of the
Virtual Grand Rounds in Radiation Oncology lectures
Recordings are 👇
youtube.com/playlist?lis...
Endorsed by:
ESTRO
DEGRO
SASRO
Virtual Grand Rounds in Radiation Oncology lectures
Recordings are 👇
youtube.com/playlist?lis...
Endorsed by:
ESTRO
DEGRO
SASRO
Virtual Grand Rounds in Radiation Oncology
„Revving Up Gastric Cancer Care: Insights from the TOPGEAR Trial”
Presented by Prof. Karin Haustermans
December 4th 17:00 – 17:30
Link to online meeting 👇
www.usz.ch/veranstaltun...
Endorsed by:
ESTRO
DEGRO
SASRO
„Revving Up Gastric Cancer Care: Insights from the TOPGEAR Trial”
Presented by Prof. Karin Haustermans
December 4th 17:00 – 17:30
Link to online meeting 👇
www.usz.ch/veranstaltun...
Endorsed by:
ESTRO
DEGRO
SASRO
November 28, 2024 at 9:17 AM
Virtual Grand Rounds in Radiation Oncology
„Revving Up Gastric Cancer Care: Insights from the TOPGEAR Trial”
Presented by Prof. Karin Haustermans
December 4th 17:00 – 17:30
Link to online meeting 👇
www.usz.ch/veranstaltun...
Endorsed by:
ESTRO
DEGRO
SASRO
„Revving Up Gastric Cancer Care: Insights from the TOPGEAR Trial”
Presented by Prof. Karin Haustermans
December 4th 17:00 – 17:30
Link to online meeting 👇
www.usz.ch/veranstaltun...
Endorsed by:
ESTRO
DEGRO
SASRO
ESTRO Scientific Council Meeting in Brussels
Hopefully in brighter colors than todays sky …
Hopefully in brighter colors than todays sky …
November 27, 2024 at 7:55 AM
ESTRO Scientific Council Meeting in Brussels
Hopefully in brighter colors than todays sky …
Hopefully in brighter colors than todays sky …
ETH Zürich Polyball
Zwischen Göttern und Menschen
Preparations almost finished
Zwischen Göttern und Menschen
Preparations almost finished
November 26, 2024 at 6:24 PM
ETH Zürich Polyball
Zwischen Göttern und Menschen
Preparations almost finished
Zwischen Göttern und Menschen
Preparations almost finished
Reposted by Matthias Guckenberger
PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.
November 25, 2024 at 2:20 PM
PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.
PEACE-1 published
Radiotherapy of the prostate in metastatic pts prevents serious GU complications, in pts with low and high tumor burden
How to select patients?
- all ?
- based on live expectancy ?
- response to systemic Tx ?
- prostate volume ?
www.thelancet.com/journals/lan...
Radiotherapy of the prostate in metastatic pts prevents serious GU complications, in pts with low and high tumor burden
How to select patients?
- all ?
- based on live expectancy ?
- response to systemic Tx ?
- prostate volume ?
www.thelancet.com/journals/lan...
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Combining radiotherapy with standard of care plus abiraterone improves radiographic
progression-free survival and castration resistance-free survival, but not overall
survival in patients with low-vol...
www.thelancet.com
November 26, 2024 at 4:59 PM
PEACE-1 published
Radiotherapy of the prostate in metastatic pts prevents serious GU complications, in pts with low and high tumor burden
How to select patients?
- all ?
- based on live expectancy ?
- response to systemic Tx ?
- prostate volume ?
www.thelancet.com/journals/lan...
Radiotherapy of the prostate in metastatic pts prevents serious GU complications, in pts with low and high tumor burden
How to select patients?
- all ?
- based on live expectancy ?
- response to systemic Tx ?
- prostate volume ?
www.thelancet.com/journals/lan...
Curious about #RadiationOncology on BlueSky
Warm welcome to all colleagues and friends !
Warm welcome to all colleagues and friends !
November 26, 2024 at 4:51 PM
Curious about #RadiationOncology on BlueSky
Warm welcome to all colleagues and friends !
Warm welcome to all colleagues and friends !